Day One Biopharmaceuticals’ (DAWN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the stock.

Several other research firms have also commented on DAWN. Oppenheimer reaffirmed a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a report on Tuesday, February 27th. Needham & Company LLC increased their target price on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a buy rating in a report on Wednesday. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a report on Monday. Finally, Piper Sandler reaffirmed an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of Moderate Buy and an average price target of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $15.19 on Wednesday. The company’s fifty day moving average price is $15.28 and its 200-day moving average price is $13.79. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities research analysts predict that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the sale, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, General Counsel Adam Dubow sold 3,242 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $49,440.50. Following the completion of the sale, the general counsel now directly owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeremy Bender sold 7,615 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the completion of the sale, the chief executive officer now directly owns 721,813 shares of the company’s stock, valued at $11,007,648.25. The disclosure for this sale can be found here. Insiders sold 55,781 shares of company stock valued at $883,160 in the last quarter. Company insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares during the period. Fisher Asset Management LLC lifted its position in Day One Biopharmaceuticals by 89.0% during the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after acquiring an additional 32,238 shares during the period. Wellington Management Group LLP lifted its position in Day One Biopharmaceuticals by 77.7% during the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares during the period. Goldman Sachs Group Inc. lifted its position in Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. Finally, Quintet Private Bank Europe S.A. lifted its position in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.